Given that extensive inhibit of RANKL expression could affect bone turnover, our study positions selective blockage of SOX5 as a potential novel therapeutic target for RA and possibly other bone resorptive diseases, such as osteoporosis. Here, TNFSF11 is linked to rheumatoid arthritis.